CUMBERLAND PHARMACEUTICALS INC 8-K

What Happened

• Cumberland Pharmaceuticals Inc. filed an 8-K on July 13, 2026, announcing a special cash dividend of $1.50 per share payable to shareholders of record as of July 23, 2026, with payment on or about July 31, 2026.
• The actions follow the closing of a Strategic Transaction with Apotex Health Corp., from which Cumberland received $100 million in cash at closing and expects up to $11 million in additional payments related to inventory and transitional support. Tax advisor analysis and updated projections showed greater net cash than originally projected, prompting the Board to return excess capital to shareholders.
• The Board also authorized an open-market share repurchase program of up to $5 million (replacing the prior $10 million program, of which $2.1 million remained available). Several directors plan to establish new share purchase plans to increase their holdings. A press release was furnished as Exhibit 99.1.

Key Details

• Special dividend: $1.50 per share
• Record date: July 23, 2026; Payment date: on or about July 31, 2026
• Cash from Apotex transaction: $100 million at closing; up to $11 million additional expected
• Share repurchase program: up to $5 million (replaces prior $10M program with $2.1M previously available)

Why It Matters

• Investors are receiving an immediate, one-time cash return through the $1.50 per-share special dividend tied to the Apotex transaction proceeds.
• The authorized $5M buyback gives management flexibility to reduce outstanding shares over time; timing and amounts will depend on stock price, trading volume, market conditions, and other business considerations disclosed in the filing.
• The filing documents a liquidity event (sale/integration of U.S.-branded businesses) that materially increased available cash and resulted in shareholder distributions and board members increasing their insider ownership.